Purine metabolic enzymes

Purine metabolic enzymes represent a broad class of proteins involved in the de novo synthesis, salvage, and catabolism of purine nucleotides, which are essential building blocks for DNA and RNA (StatPearls, 2023). These enzymes, including inosine-5'-monophosphate dehydrogenase (IMPDH) and xanthine oxidase, regulate the cellular pools of ATP and GTP required for energy metabolism and intracellular signaling (NCBI, 2022). Because rapidly dividing cells, such as cancer cells and activated lymphocytes, have a high demand for purines, these enzymes are critical therapeutic targets (PubMed, 2021). Drugs targeting this pathway often act as antimetabolites or enzyme inhibitors to disrupt nucleic acid synthesis or lower metabolic byproducts like uric acid (NIH, 2023). For instance, thiopurines and methotrexate are widely used in oncology and rheumatology to induce cell cycle arrest or apoptosis in target populations (PubChem, 2024). Additionally, inhibitors of xanthine oxidase are the standard of care for managing hyperuricemia and gout by preventing the overproduction of uric acid (StatPearls, 2023).

Other names

Purine biosynthesis enzymesPurine salvage pathway enzymesPurine catabolic enzymesPurine metabolism proteins

Inhibition of key enzymes in the de novo purine biosynthetic pathway (e.g., IMPDH, DHFR) or the salvage pathway, and the competitive inhibition of purine catabolic enzymes (e.g., xanthine oxidase) to reduce uric acid production or deplete nucleotide pools for DNA/RNA synthesis.